Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 333

1.

Coenzyme Q-10 in Human Health: Supporting Evidence?

Saha SP, Whayne TF Jr.

South Med J. 2016 Jan;109(1):17-21. doi: 10.14423/SMJ.0000000000000393. Review.

PMID:
26741866
2.

[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].

Toth A, Nagy H, Wacha J, Bereczki D, Takáts A.

Neuropsychopharmacol Hung. 2015 Dec;17(4):191-6. Review. Hungarian.

3.

Cognitive training in Parkinson disease: A systematic review and meta-analysis.

Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A.

Neurology. 2015 Nov 24;85(21):1843-51. doi: 10.1212/WNL.0000000000002145. Epub 2015 Oct 30. Review.

4.

Extrapyramidal Reactions Associated with Serotonergic Antidepressants.

Hawthorne JM, Caley CF.

Ann Pharmacother. 2015 Oct;49(10):1136-52. doi: 10.1177/1060028015594812. Epub 2015 Jul 16. Review.

PMID:
26185277
5.

Role of 5-hydroxymethylcytosine in neurodegeneration.

Sherwani SI, Khan HA.

Gene. 2015 Oct 1;570(1):17-24. doi: 10.1016/j.gene.2015.06.052. Epub 2015 Jun 23. Review.

PMID:
26115768
6.

Depression rating scales in Parkinson's disease: A critical review updating recent literature.

Torbey E, Pachana NA, Dissanayaka NN.

J Affect Disord. 2015 Sep 15;184:216-24. doi: 10.1016/j.jad.2015.05.059. Epub 2015 Jun 10. Review.

PMID:
26114228
7.

Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.

Kelly MJ, O'Keeffe GW, Sullivan AM.

Expert Rev Mol Med. 2015 May 13;17:e8. doi: 10.1017/erm.2015.6. Review.

PMID:
25997719
8.

Neuronal Network Oscillations in Neurodegenerative Diseases.

Nimmrich V, Draguhn A, Axmacher N.

Neuromolecular Med. 2015 Sep;17(3):270-84. doi: 10.1007/s12017-015-8355-9. Epub 2015 Apr 29. Review.

PMID:
25920466
9.

Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

More SV, Choi DK.

Mol Neurodegener. 2015 Apr 8;10:17. doi: 10.1186/s13024-015-0012-0. Review.

10.

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, Albin RL, Frey KA.

Mov Disord. 2015 Jun;30(7):928-35. doi: 10.1002/mds.26191. Epub 2015 Apr 16. Review.

11.

A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease.

Cruickshank TM, Reyes AR, Ziman MR.

Medicine (Baltimore). 2015 Jan;94(4):e411. doi: 10.1097/MD.0000000000000411. Review.

12.

[Parkinson's disease and psychoses].

Bizzarri JV, Giupponi G, Maniscalco I, Schroffenegger P, Conca A, Kapfhammer HP.

Neuropsychiatr. 2015;29(1):1-13. doi: 10.1007/s40211-014-0132-8. Epub 2015 Jan 14. Review. German.

PMID:
25586068
13.

Molecular imaging in genetics.

Leite J, Hespanhol R, Buchpiguel CA.

Neuroimaging Clin N Am. 2015 Feb;25(1):17-29. doi: 10.1016/j.nic.2014.09.005. Epub 2014 Oct 18. Review.

PMID:
25476510
14.

[Potential analysis for research on physiotherapy-led treadmill training in Parkinson's disease].

Lohkamp M, Braun C, Wasner M, Voigt-Radloff S.

Z Evid Fortbild Qual Gesundhwes. 2014;108 Suppl 1:S29-35. doi: 10.1016/j.zefq.2014.09.005. Epub 2014 Oct 8. Review. German.

PMID:
25458396
15.

Addictions comportementales dans la maladie de Parkinson.

Corvol JC.

Bull Acad Natl Med. 2014 Oct;198(7):1297-307; discussion 1307-8. Review. French.

PMID:
27120903
16.

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.

Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L.

Int J Neurosci. 2015;125(9):645-54. doi: 10.3109/00207454.2014.961454. Epub 2014 Oct 2. Review.

PMID:
25202803
17.

Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.

Beggiato S, Antonelli T, Tomasini MC, Borelli AC, Agnati LF, Tanganelli S, Fuxe K, Ferraro L.

Curr Protein Pept Sci. 2014;15(7):673-80. Review.

PMID:
25175458
18.

Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.

Ferraro L, Beggiato S, Borroto-Escuela DO, Ravani L, O'Connor WT, Tomasini MC, Borelli AC, Agnati LF, Antonelli T, Tanganelli S, Fuxe K.

Curr Protein Pept Sci. 2014;15(7):681-90. Review.

PMID:
25175457
19.

The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies.

Xie CL, Pan JL, Wang WW, Zhang Y, Zhang SF, Gan J, Liu ZG.

Neurol Sci. 2014 Oct;35(10):1495-504. doi: 10.1007/s10072-014-1878-2. Epub 2014 Jul 16. Review.

PMID:
25027012
20.

Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Shu HF, Yang T, Yu SX, Huang HD, Jiang LL, Gu JW, Kuang YQ.

PLoS One. 2014 Jul 1;9(7):e100503. doi: 10.1371/journal.pone.0100503. eCollection 2014. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk